Post by jeffnny on Oct 6, 2005 21:06:28 GMT -5
Phase IIb clinical trials are expected to be national and start the end of this year, or the first of next year…look for news on our website.
Good question regarding “Tovaxin used additionally to prevent other problems.”
So far our research shows that the attenuated T Cells used in the Tovaxin drug only cause an autoimmune reaction to identical T Cells. These identical T Cells are the offending T Cells in MS.
I think you could be asking if the technology could be used in other autoimmune diseases. We believe the answer is yes.
Best regards,
Bill
C. William Rouse, CFO
PharmaFrontiers Corp (PFTR.OB)
2408 Timberloch Place Suite B7
The Woodlands, TX 77380
After 10/7/05 Address will change to:
2635 N Crescent Ridge Drive
The Woodlands TX 77381
www.pharmafrontierscorp.com
PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as cardiac and pancreatic conditions and Multiple Sclerosis.
......CONFIDENTIALITY NOTICE...... The information in this email may be confidential and/or privileged. This email is intended to be reviewed by only the individual or organization named above. If you are not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any review, dissemination or copying of this email and its attachments, if any, or the information contained herein is prohibited. If you have received this email in error, please immediately notify the sender by return email and delete this email from your system.
--------------------------------------------------------------------------------
From: Jeff [mailto:]
Sent: Thursday, October 06, 2005 3:20 PM
To: Bill Rouse
Subject: I have a question
Tovaxin seems promising. Tim surely has made it known online. I see the clinical trials I/II were inhouse. I couldn't find them in any of the clinical trial sites nor on the FDA site. I am an MSer with RR MS. When will there be news from your company concerning the expansion to a FDA approved clinical III trial? Will that trial be localized or expanded worldwide? My neuro is the head of MS at SUNY Healthcare Center in Syracuse NY. Though Tysabri seemed to be a success, I will never use it. None the less. I dont mean to take up your time. I'm not looking for a magic bullet, but having been on Avonex and Betaseron (still) and progressing more since being on them one has to wonder. What I like about tovaxin is its individualized. Only one quesition to consider from a potential consumers point of view.....The are the T-Cells affected by Tovaxin used additionally to prevent other problems? AND, would it be worth the risk. No answer is necessary. Thanks for listening.
Jeff Shepard
Good question regarding “Tovaxin used additionally to prevent other problems.”
So far our research shows that the attenuated T Cells used in the Tovaxin drug only cause an autoimmune reaction to identical T Cells. These identical T Cells are the offending T Cells in MS.
I think you could be asking if the technology could be used in other autoimmune diseases. We believe the answer is yes.
Best regards,
Bill
C. William Rouse, CFO
PharmaFrontiers Corp (PFTR.OB)
2408 Timberloch Place Suite B7
The Woodlands, TX 77380
After 10/7/05 Address will change to:
2635 N Crescent Ridge Drive
The Woodlands TX 77381
www.pharmafrontierscorp.com
PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as cardiac and pancreatic conditions and Multiple Sclerosis.
......CONFIDENTIALITY NOTICE...... The information in this email may be confidential and/or privileged. This email is intended to be reviewed by only the individual or organization named above. If you are not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any review, dissemination or copying of this email and its attachments, if any, or the information contained herein is prohibited. If you have received this email in error, please immediately notify the sender by return email and delete this email from your system.
--------------------------------------------------------------------------------
From: Jeff [mailto:]
Sent: Thursday, October 06, 2005 3:20 PM
To: Bill Rouse
Subject: I have a question
Tovaxin seems promising. Tim surely has made it known online. I see the clinical trials I/II were inhouse. I couldn't find them in any of the clinical trial sites nor on the FDA site. I am an MSer with RR MS. When will there be news from your company concerning the expansion to a FDA approved clinical III trial? Will that trial be localized or expanded worldwide? My neuro is the head of MS at SUNY Healthcare Center in Syracuse NY. Though Tysabri seemed to be a success, I will never use it. None the less. I dont mean to take up your time. I'm not looking for a magic bullet, but having been on Avonex and Betaseron (still) and progressing more since being on them one has to wonder. What I like about tovaxin is its individualized. Only one quesition to consider from a potential consumers point of view.....The are the T-Cells affected by Tovaxin used additionally to prevent other problems? AND, would it be worth the risk. No answer is necessary. Thanks for listening.
Jeff Shepard